Passage Bio
United States · $225.5M raised
- Website
- passagebio.com
- Total Funding
- $225.5M
- Last Round
- $110.0M Series BSep 2019
- Rounds
- 2
About
Passage Bio is a clinical-stage genetic medicines company developing therapies for rare central nervous system disorders. Its programs use gene-therapy approaches intended to address diseases associated with mutated or nonfunctional genes. The company focuses on advancing treatments for neurodegenerative conditions and improving outcomes for patients and families affected by severe neurologic disease.
Summary
Passage Bio is a Biotech company based in United States. It has raised $225.5M in total across 2 rounds, most recently a $110.0M Series B round in Sep 2019.
Funding History
Sep 2019
Sign up to see all 2 rounds
Series A through Series B — per-round amounts, valuations, and who invested in each round.
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/passage-bio"><img src="https://indexed.vc/api/badge/company/passage-bio" alt="Passage Bio on Indexed.vc" width="260" height="76" /></a>